Detalhe da pesquisa
1.
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
Br J Haematol
; 192(3): 568-576, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33341940
2.
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
Br J Haematol
; 188(2): 283-294, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31423579
3.
Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
BMC Cardiovasc Disord
; 20(1): 430, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33004000
4.
Exploration of Novel Biomarkers in Vasculitis by Integrated Bioinfomatic Approaches.
J Comput Biol
; 26(12): 1448-1457, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31356108